Enlivex to Present at Upcoming Investor and Media Conferences
09/13/2022 - 08:00 AM
Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will be presenting at the following investor and media conferences in September.
H.C. Wainwright 24th Annual Global Investment Conference
Presentation Format: Corporate Presentation Date & Time: September 13, 2022, at 11:00 AM ET Location: Lotte New York Palace Hotel Webcast Link: Here
Baird’s 2022 Global Healthcare Conference
Presentation Format: Corporate Presentation Date & Time: September 14, 2022, at 3:10 PM ET Location: InterContinental New York Barclay Webcast Link: Here
Cantor Cell and Genetic Medicines Conference
Presentation Format: Panel Discussion Panel Title: CAR-T and Beyond: What Are the Next Generation Cell Therapies? Date & Time: September 15, 2022, at 9:20 AM ET Location: Lotte New York Palace Hotel
Company management will be available for 1x1 investor meetings during the Cantor and H.C. Wainwright events. Those interested in requesting a meeting during the conferences should contact their respective event representative.
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit https://enlivex.com/
ENLIVEX CONTACT shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT eric@lifesciadvisors.com
ENLV Rankings
#5111 Ranked by Stock Gains
ENLV Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Biotechnology, Medical Specialties, Health Technology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Israel
City
14 Einstein St
About ENLV
enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib clinical trial in patients with severe sepsis; that is in investigator-initiated phase ii clinical trial for the treatment of covid-19 patients in severe and critical conditions; and which is in phase iia clinical trial for the prevention of graft versus host disease in allogeneic hematopoietic stem cell transplants (hsct) patients. the company is also developing allocetra for the prevention of complications associated with bone marrow transplantations and/or hsct, and acute multiple organ failure. it also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor t-cell therapy and therapies targeting t-cell re
